Petros Grivas, Clinical Director of the GU Cancer Program at the University of Washington, shared a post on X:
“My colleague Dr. Nadal covered bladder cancer updates from ASCO 2026 and more! Durvalumab FDA approved for BCG-naive HR NMIBC; NIAGARA, KN905, KNB15, RAD-IO in MIBC; EV302 longer follow-up.”
Other articles featuring Dr. Grivas on OncoDaily.
